AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03015545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paretic leg-control
Description: standing on the vibration platform, with no vibration signals delivered.
Study NCT00178360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art
Study NCT03015545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paretic leg-WBV
Description: standing on the vibration platform, with WBV at 30Hz, 1.5mm.
Study NCT03015545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-paretic leg-control
Description: standing on the vibration platform, with no vibration signals delivered.
Study NCT03015545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-paretic leg-WBV
Description: standing on the vibration platform, with WBV at 30Hz, 1.5mm.
Study NCT03854435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate assessment (stethoscope)
Description: Immediately after birth heart rate will be evaluated by auscultation
Study NCT03854435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart assessment (umbilical cord palpation)
Description: Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
Study NCT00203242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depacon IV and Depakote ER
Study NCT04960410 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Types and exposure of different air pollutants
Description: Types and exposure of different air pollutants in COPD patients' living and working environment
Study NCT03708185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: N/A: see arm description
Study NCT03708185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: N/A: see arm description
Study NCT01583543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 400mg PO BID Continuous
Study NCT04160481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FruitFlow
Description: 300mg tomato extract
Study NCT04160481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500 international units/m2/day IM or IV on days 10 and 24.
Study NCT01483690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35
Study NCT00503438 — intervention group
Intervention type: DEVICE
Intervention: Salto Talaris Ankle
Description: Salto Talaris Anatomic Ankle total joint prosthesis
Study NCT02746068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-02
Study NCT02746068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03392532 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses with HYDRAGLYDE
Description: Silicone hydrogel soft contact lenses for astigmatism
Study NCT03392532 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lenses
Description: Silicone hydrogel soft contact lenses for astigmatism
Study NCT04217785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optive, Ophthalmic Solution
Description: 6 drops per day, for 8 weeks
Study NCT04217785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Serum eye drops
Description: UCS eye drops (6 drops per day, for 8 weeks)
Study NCT04217785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genteal lubricant gel
Description: Genteal lubricant gel (2 drops per day, for 8 weeks)
Study NCT00978432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 10 mg/day for Part 1 of the trial
Study NCT00978432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
Study NCT00978432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doublet (RAD001 and LBH589)
Description: RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
Study NCT02172066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Study NCT03659786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
Study NCT00749580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch NRTIs as a Backbone to Raltegravir
Description: This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
Study NCT04520893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilator setting vcv with pause
Description: ventilator setting vcv with pause
Study NCT04520893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator setting vcv
Description: ventilator setting vcv without pause
Study NCT04520893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator setting pcv-vg
Description: ventilator setting with pcv-vg
Study NCT03619343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)
Description: When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
Study NCT03619343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)
Description: When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
Study NCT03004222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of 0.5% Bupivacaine
Study NCT03004222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03718182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: vitamin D3 daily oral supplement
Study NCT03718182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: vitamin D3 daily oral supplement
Study NCT04962542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ventilation
Description: low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
Study NCT03959540 — intervention group
Intervention type: DRUG
Intervention: Opicapone
Description: Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
Study NCT03959540 — intervention group
Intervention type: DRUG
Intervention: Levodopa (L-DOPA) + Standard care
Description: Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
Study NCT03670927 — intervention group
Intervention type: OTHER
Intervention: Environmental, occupational and lifestyle-related exposures
Description: A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
Study NCT02869061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT02869061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral bladder neck resection.
Study NCT02869061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADRC
Description: Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
Study NCT02869061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
Study NCT01886716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Attention Training
Description: Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
Study NCT03080220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astym
Description: therapeutic massage instrument
Study NCT03080220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stick
Description: massage instrument
Study NCT03080220 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Massage
Description: massage instruments
Study NCT02775058 — intervention group
Intervention type: DEVICE
Intervention: synergoss Pxx
Description: dental grafting
Study NCT04522245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss.
Description: The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging.
Study NCT04522245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Control
Description: Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
Study NCT01706809 — intervention group
Intervention type: OTHER
Intervention: blood sampels from vena rectalis superior and vena cubiti
Study NCT01237080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope
Description: The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
Study NCT01237080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fastrach
Description: The Fastrach is an intubation laryngeal mask.
Study NCT02531490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Study NCT02531490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Study NCT02531490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyldopa
Study NCT00566722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
Study NCT05578794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straining types
Description: Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
Study NCT01272024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Education
Description: Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
Study NCT01272024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
Study NCT00645827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IICE Dosing
Description: Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
Study NCT00645827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Provider dosing
Description: Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
Study NCT04411017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Colonoscopy
Study NCT00676650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg BID, oral
Study NCT00676650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Study NCT01886716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Attention Training
Description: Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
Study NCT01886716 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
Study NCT00850161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspart
Description: Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
Study NCT00850161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasulin™
Description: 100 IU(2 puffs in each nostril)
Study NCT04007887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult education program
Description: A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
Study NCT04145687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg tid
Study NCT04145687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg tid
Study NCT02993497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared camera
Description: In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
Study NCT02993497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RVM(Respiratory Volume Monitor)
Description: In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
Study NCT01750996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families
Description: Behavioural intervention
Study NCT01085487 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Women using Mirena for treatment of menorrhagia
Study NCT00090051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous repeating dose
Study NCT02219555 — intervention group
Intervention type: DRUG
Intervention: Steroid Injection
Description: volume and specific steroid drug will be based on the recommendation of the treating clinician
Study NCT01019174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
Study NCT01254539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminectomy and bone marrow stem cells transplantation
Description: Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
Study NCT01254539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of autologous bone marrow stem cells
Description: Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
Study NCT01254539 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal infusion of placebo (saline solution).
Description: Patients were infused 2 ml of saline solution
Study NCT00615160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
Study NCT00615160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 850 mg/m² on day 1 q4w
Study NCT03574389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13vPnC
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study NCT03574389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study NCT03593278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-246475
Description: Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
Study NCT00625105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Study NCT00625105 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Biofeedback